These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 14728059)

  • 1. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders.
    Stanton A
    Am J Cardiovasc Drugs; 2003; 3(6):389-94. PubMed ID: 14728059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of renin inhibition in cardiovascular disease.
    Stanton A
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):6-10. PubMed ID: 12692747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical potential of renin inhibitors and angiotensin antagonists.
    Cody RJ
    Drugs; 1994 Apr; 47(4):586-98. PubMed ID: 7516858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of angiotensin II inhibition in cardiovascular medicine.
    Meier P; Maillard M; Burnier M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):15-30. PubMed ID: 15720221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the renin-angiotensin system.
    Cheung BM
    Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system.
    Hollenberg NK; Fisher ND; Price DA
    Hypertension; 1998 Sep; 32(3):387-92. PubMed ID: 9740600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
    Cody RJ
    Drugs; 1984 Aug; 28(2):144-69. PubMed ID: 6205842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.